Enliven Therapeutics (NASDAQ:ELVN) Posts Quarterly Earnings Results

Enliven Therapeutics (NASDAQ:ELVN) posted its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10), FiscalAI reports.

Enliven Therapeutics Trading Down 2.3%

NASDAQ:ELVN traded down $1.41 on Wednesday, hitting $59.70. 1,724,207 shares of the stock were exchanged, compared to its average volume of 1,287,011. The stock has a fifty day moving average of $47.45 and a 200-day moving average of $39.05. The stock has a market cap of $3.64 billion, a PE ratio of -35.75 and a beta of 0.27. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ELVN. The Goldman Sachs Group lifted their price objective on Enliven Therapeutics from $59.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. HC Wainwright increased their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. JonesTrading lifted their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Mizuho lifted their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Insider Activity

In other news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,036 shares of company stock worth $1,430,676 over the last ninety days. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in the business. Invesco Ltd. lifted its holdings in shares of Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after acquiring an additional 913 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Swiss National Bank increased its holdings in Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares in the last quarter. Quantbot Technologies LP raised its position in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Finally, Legal & General Group Plc raised its position in Enliven Therapeutics by 4.8% in the third quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock valued at $691,000 after purchasing an additional 1,540 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.